PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY APPLICATION
• Segmentation by application
• Comparison by application
• Neurological disorders – Market size and forecast 2017-2022
• Cancer – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Market opportunity by application
PART 08: MARKET SEGMENTATION BY TECHNOLOGY
• Segmentation by technology
• Comparison by technology
• Antisense/RNAi oligonucleotides – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Market opportunity by technology
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Key leading countries
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Increasing M&A
• Advances in DNA sequencing increases use of microfluidic techniques
• Increasing drugs in pipeline
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Arrowhead Pharmaceuticals
• GlaxoSmithKline
• Ionis Pharmaceuticals
• miRagen Therapeutics
• Sarepta Therapeutics
PART 16: APPENDIX
• List of abbreviations


Exhibit 01: Related market
Exhibit 02: Market characteristics
Exhibit 03: Market segments
Exhibit 04: Market definition - Inclusions and exclusions checklist
Exhibit 05: Market size 2017
Exhibit 06: Validation techniques employed for market sizing 2017
Exhibit 07: Global – Market size and forecast 2017-2022 ($ mn)
Exhibit 08: Global – Year-over-year growth 2018-2022 (%)
Exhibit 09: Five forces analysis 2017
Exhibit 10: Five forces analysis 2022
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2017
Exhibit 17: Application – Market share 2017-2022 (%)
Exhibit 18: Comparison by application
Exhibit 19: Neurological disorders – Market size and forecast 2017-2022 ($ mn)
Exhibit 20: Neurological disorders – Year-over-year growth 2018-2022 (%)
Exhibit 21: Cancer – Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Cancer – Year-over-year growth 2018-2022 (%)
Exhibit 23: Others – Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Others – Year-over-year growth 2018-2022 (%)
Exhibit 25: Market opportunity by application
Exhibit 26: Technology – Market share 2017-2022 (%)
Exhibit 27: Comparison by technology
Exhibit 28: Antisense/RNAi oligonucleotides – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Antisense/RNAi oligonucleotides – Year-over-year growth 2018-2022 (%)
Exhibit 30: Others – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Others – Year-over-year growth 2018-2022 (%)
Exhibit 32: Market opportunity by technology
Exhibit 33: Customer landscape
Exhibit 34: Global – Market share by geography 2017-2022 (%)
Exhibit 35: Regional comparison
Exhibit 36: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 38: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 39: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 40: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 41: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Cost of sequencing per genome in $ (2001-2015)
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Arrowhead Pharmaceuticals overview
Exhibit 51: Arrowhead Pharmaceuticals – Product segments
Exhibit 52: Arrowhead Pharmaceuticals – Organizational developments
Exhibit 53: Arrowhead Pharmaceuticals – Key offerings
Exhibit 54: GlaxoSmithKline overview
Exhibit 55: GlaxoSmithKline – Business segments
Exhibit 56: GlaxoSmithKline – Organizational developments
Exhibit 57: GlaxoSmithKline – Geographic focus
Exhibit 58: GlaxoSmithKline – Segment focus
Exhibit 59: GlaxoSmithKline – Key offerings
Exhibit 60: Ionis Pharmaceuticals overview
Exhibit 61: Ionis Pharmaceuticals – Business segments
Exhibit 62: Ionis Pharmaceuticals – Organizational developments
Exhibit 63: Ionis Pharmaceuticals – Segment focus
Exhibit 64: Ionis Pharmaceuticals – Key offerings
Exhibit 65: miRagen Therapeutics overview
Exhibit 66: miRagen Therapeutics – Business segments
Exhibit 67: miRagen Therapeutics – Organizational developments
Exhibit 68: miRagen Therapeutics – Key offerings
Exhibit 69: Sarepta Therapeutics overview
Exhibit 70: Sarepta Therapeutics – Business segments
Exhibit 71: Sarepta Therapeutics – Organizational developments
Exhibit 72: Sarepta Therapeutics – Key offerings

Arrowhead Pharmaceuticals, GlaxoSmithKline, Ionis Pharmaceuticals, miRagen Therapeutics, Sarepta Therapeutics.